# Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Source: https://onco.cc/trials/nct07252232/  
OnCo record `nct07252232` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 3 interventional study registered as NCT07252232 by Revolution Medicines, Inc., with 500 participants planned, started 2025-12-15 and due to reach its primary completion in 2029-05-10. Interventions recorded: daraxonrasib. Conditions listed: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: RASolute 304
- Tags: ctgov-ingest
- Registry id: NCT07252232
- Phase: 3
- Setting: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 500

## Notes

- RASolute 304 (registry, 24 September 2026): phase 3 of adjuvant daraxonrasib against observation after neoadjuvant and/or adjuvant chemotherapy in resected pancreatic ductal adenocarcinoma; 500 participants (estimated), recruiting, started 15 December 2025, primary completion May 2029, disease-free survival by investigator. UK sites (6): University Hospitals Birmingham (Queen Elizabeth), Beatson West of Scotland Cancer Centre Glasgow, Clatterbridge Liverpool, Royal Marsden London, Hammersmith (Imperial), the Christie Manchester.

## Sources

- ClinicalTrials.gov NCT07252232: https://clinicaltrials.gov/study/NCT07252232

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- trials: [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [RASolute 302](https://onco.cc/trials/rasolute-302/)
- key papers: [Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [Off-the-shelf KRAS vaccines after pancreatic cancer surgery](https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/), [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)

---
JSON: https://onco.cc/api/v1/entities/nct07252232.json